Oncimmune Holdings plc has placed and converted debt into equity
Oncimmune Holdings plc has raised US$2.9 million (£2.3 million) by placing and converting debt into equity to advance its pioneering work in autoantibody profiling and biomarker discovery, along with an additional US$4.1 million (€4 million) from debt conversion.
Oncimmune Holdings plc develops and commercializes technologies for cancer diagnosis in the UK, North America, Europe and beyond. The company offers EarlyCDT-Lung, a blood test for the early detection of lung cancer. Additionally, Oncimmune develops SeroTag, a platform for discovering and validating biomarkers to help stratify patients across multiple cancer indications, infectious diseases and autoimmune conditions. The company also offers NavigAID disease-specific stratification panels. Founded in 2015, Oncimmune is based in Nottingham, UK.
Oaklins Cavendish, one of Oaklins’ member firms in the UK, advised Oncimmune Holdings plc on this transaction.
Contacter l'équipe de la transaction
Transactions connexes
Banco BPM Vita S.p.A. has launched a voluntary public tender offer for Anima Holding S.p.A.
Banco BPM Vita S.p.A. has initiated a voluntary public tender offer for the shares of Anima Holding S.p.A.
En apprendre plusTerra Holding S.r.l. has launched a voluntary public tender offer for Gibus S.p.A.
Terra Holding S.r.l. has initiated a voluntary public tender offer for the shares of Gibus S.p.A.
En apprendre plusPharma-Skan & Skan-Medic have been acquired by Brygge Partners
Pharma-Skan, an independent contract manufacturing organization (CMO), and Skan-Medic, a manufacturer of over-the-counter (OTC) products, both operating as a joint entity, have been acquired by Brygge Partners.
En apprendre plus